Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients.

Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients. Abstract Text:

M Thaha, Widodo,W Pranawa,M Yogiantoro,Y Tomino,M Thaha, Widodo,W Pranawa,M Yogiantoro,Y Tomino,

Aim: Cardiovascular disease is the main cause of mortality in chronic kidney disease patients. Moreover, uremic patients are in a pro-oxidant state and show an increase in asymmetric dimethylarginine (ADMA) levels due to inhibition of the enzyme dimethylarginine dimethylaminohydrolase (DDAH). Asymmetric dimethylarginine per se seems responsible for a 52% increase in the risk of death and for a 34% increase in the risk of cardiovascular events in dialysis patients. N-acetylcysteine (NAC) is a thiol molecule that has direct and indirect antioxidant effects which decrease reactive oxidant species and increase the bioavailability of the DDAH enzyme. The aim of the current study was to determine the effect of intravenous NAC on plasma ADMA level when administered during hemodialysis in end-stage renal disease (ESRD) patients. Materials and methods: 40 patients with ESRD were randomized to receive a 4-hour intravenous infusion of NAC or placebo during a 4-hour hemodialysis session. There were 3 diabetic patients (15%) in the treatment group and 6 patients in the control group. Plasma ADMA levels were measured before and immediately after hemodialysis. Hemodynamic parameters, including pulse pressure, were also measured. The paired t-test was used to compare the difference of ADMA levels before and after hemodialysis in each group, while the independent t-test was used to compare the difference of ADMA levels between the groups. Results: Compared with the pre-dialysis condition, there was a decrease of ADMA level in the control group (1.1253 A+/- 0.1797 AmicroM to 0.8676 A+/- 0.1449 AmicroM) (p < 0.001), and in the NAC group (1.1522 A+/- 0.1737 AmicroM to 0.7844 A+/- 0.1586 AmicroM) (p < 0.001). Compared with hemodialysis alone, NAC had a greater lowering effect on the ADMA level (21.3 vs. 31.9%, p < 0.05). Conclusion: N-acetylcysteine (NAC) administered intravenously during hemodialysis reduced asymmetric dimethylarginine (ADMA) levels more significantly than hemodialysis alone.

Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients. Publishing Authors By Initials

M Thaha, Widodo,W Pranawa,M Yogiantoro,Y Tomino,M Thaha, Widodo,W Pranawa,M Yogiantoro,Y Tomino,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Clinical nephrology

VOLUME: 69

Page Numbers: 24-32

Journal Abbreviation: Clin. Nephrol.

ISSN: 0301-0430

DAY: 29

MONTH: Jan

YEAR: 2008

Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 364441

Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients.

AFFILIATION: 1Division of Nephrology-Hypertension, Department of Internal Medicine, Airlangga University School of Medicine, Surabaya, Indonesia and 2Division of Nephrology, Department of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan.

Country: Germany

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Nephrol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients Related Publications

• Amelioration of Crescentic Glomerulonephritis by RhoA Kinase Inhibitor, Fasudil, through Podocyte Protection and Prevention of Leukocyte Migration.
• Analysis of IgA nephropathy by serial renal biopsies in the ddY mouse: heterogeneous progression of glomerulonephritis.
• Antibiotics induce apoptosis of human peritoneal mesothelial cells.
• Biosynthesis of tropomyosin and troponin during development of the chicken skeletal muscle.
• Effect of educational hospitalization on chronic kidney disease (CKD) patients.
• Effect of pitavastatin on type 2 diabetes mellitus nephropathy in KK-A(y)/Ta mice.
• Evaluation of parathyroid hyperplasia by ultrasonographic examination in patients with end-stage renal failure before and at initiation of dialysis.
• Improvement of peritoneal calcification after parathyroidectomy in a peritoneal dialysis patient.
• Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats.
• Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients.
• Leukocytapheresis (LCAP) for the treatment of rheumatoid arthritis on a maintenance hemodialysis patient.
• Osteodystrophy in Indonesian haemodialysis patients.
• Peritoneal fibrosis intervention.
• Peritubular ischemia contributes more to tubular damage than proteinuria in immune-mediated glomerulonephritis.
• Possible involvement of mast cells in renal fibrosis in patients with IgA nephropathy.
• Potential immunopathogenic role of the mucosa-bone marrow axis in IgA nephropathy: insights from animal models.
• Prediction of diagnosis of immunoglobulin a nephropathy prior to renal biopsy and correlation with urinary sediment findings and prognostic grading.
• Preoperative autologous blood donation for cardiac surgery in children.
• Re-operation for Tetralogy of Fallot with Single Right Coronary Artery.
• Reduction of 2,4-disubstituted resorcinols.
• Relationship between Abdominal Fat Accumulation and Insulin Resistance in Hemodialysis Patients.
• STUDIES ON ORNITHINE-KETOACID TRANSAMINASE. I. PURIFICATION AND PROPERTIES.
• Suppressive activity of pemirolast potassium, an antiallergic drug, on glomerulonephritis. Studies in glomerulonephritis model rats and in patients with chronic glomerulonephritis concurrently affected by allergic rhinitis.
• The role of podocytes in proteinuria.
• [A case of left atrial myxoma with acute myocardial infarction--emergency coronary artery bypass grafting and removal of left atrial myxoma]
• [A case of mitral valve replacement for Libman-Sacks endocarditis]
• [Chronic glomerulonephritis]
• [Overview of IgA nephropathy]
• [Pathogenesis of IgA nephropathy: current understanding of mucosa-bone marrow axis in IgA nephropathy]
• [Pulsatile extracorporal circulation. Experimental section: experimental study and designing of the apparatus]